SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data for the ongoing phase 3 pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial, has been reached. Final data analysis in preparation for un-blinding is underway, and the company expects to report top-line data early in the fourth quarter of 2011.
